Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seladelpar Dose-Ranging Study in PBC
NCT02955602Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of seladelpar in primary biliary cholangitis (PBC) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at 8 weeks. Started Nov 2016; status: completed.
02
Drugs
seladelpar
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02955602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955602.